Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (odpre novo okno)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Vir‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indeksirano‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (odpre novo okno)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (odpre novo okno)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Vir‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indeksirano‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (odpre novo okno)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (odpre novo okno)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Vir‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indeksirano‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (odpre novo okno)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (odpre novo okno)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Vir‎: Blood 2003;102(4):1529-30.

Indeksirano‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (odpre novo okno)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (odpre novo okno)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Vir‎: Transfusion 2007;47(10):1830-6.

Indeksirano‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (odpre novo okno)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (odpre novo okno)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Vir‎: Iran J Blood Cancer 2009;1(4):147-50.

Indeksirano‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (odpre novo okno)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (odpre novo okno)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Vir‎: Int J Hematol 2012;95(1):51-6.

Indeksirano‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (odpre novo okno)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (odpre novo okno)

Perrine SP.

Vir‎: Pediatr Ann 2008;37(5):339-46.

Indeksirano‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (odpre novo okno)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (odpre novo okno)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Vir‎: Sci Rep. 2022;12(1):2752.

Indeksirano‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (odpre novo okno)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (odpre novo okno)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Vir‎: Haematologica 2004;89(10):1172-8.

Indeksirano‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (odpre novo okno)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (odpre novo okno)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Vir‎: Arch Iran Med 2009;12(3):295-7.

Indeksirano‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (odpre novo okno)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (odpre novo okno)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Vir‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indeksirano‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (odpre novo okno)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (odpre novo okno)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Vir‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indeksirano‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (odpre novo okno)

Fetal globin gene inducers: novel agents and new potential. (odpre novo okno)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Vir‎: Ann N Y Acad Sci 2010;1202:158-64.

Indeksirano‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (odpre novo okno)